Vertex Pharmaceuticals (VRTX) Change in Receivables (2009 - 2026)

Vertex Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at -$39.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 123.47% year-over-year to -$39.8 million; the TTM figure through Mar 2026 stood at $137.9 million (up 697.11% YoY), while the FY2025 annual figure was $347.3 million, up 249.75% from the prior year.
• Change in Receivables was -$39.8 million for Q1 2026 at Vertex Pharmaceuticals, down from $99.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $251.6 million in Q1 2024 to a low of -$135.1 million in Q2 2024.
• Historically, Change in Receivables has averaged $50.0 million across 5 years, with a median of $51.8 million in 2024.
• Biggest YoY gain for Change in Receivables was 749.18% in 2024; the steepest drop was 4758.62% in 2024.
• A 5-year view of Change in Receivables shows it stood at -$10.2 million in 2022, then slumped by 50.98% to -$15.4 million in 2023, then slumped by 348.05% to -$69.0 million in 2024, then soared by 244.06% to $99.4 million in 2025, then plunged by 140.04% to -$39.8 million in 2026.
• The last three Change in Receivables figures came in at -$39.8 million (Q1 2026), $99.4 million (Q4 2025), and $59.9 million (Q3 2025), per Business Quant data.